19 March 2021
Hogan Lovells advises Gilead Sciences in long-acting HIV therapy collaboration agreement with Merck
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Cullen Taylor Lead | Hogan Lovells Cadwalader | Partner | Life Sciences Transactions | Northern Virginia |
| Lauren Battaglia | Hogan Lovells Cadwalader | Partner | Antitrust, Competition, and Economic Regulation | Washington, D.C. |
| Falk Schöning | Hogan Lovells Cadwalader | Partner | Antitrust, Competition, and Economic Regulation | Brussels |
| Dan Davidson | Hogan Lovells Cadwalader | Counsel | Tax, Pensions & Benefits | Washington, D.C. |
| Nadia Aksentijevich | Hogan Lovells Cadwalader | Senior associate | Intellectual Property, Media, Telecommunications | Washington, D.C. |
| Rachel Eisen | Hogan Lovells Cadwalader | Associate | Intellectual Property, Media, Telecommunications | Northern Virginia |
| Estefania McCarroll | Hogan Lovells Cadwalader | Associate | Intellectual Property, Media, Telecommunications | Northern Virginia |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Gilead SciencesJoint venture party
- Counterparties
- Merck & Co. (Joint venture party)